Panacea Biotec Ltd (PANACEABIO) — FY26 Annual Report | 7 September 2026 (2 announcements)

Panacea Biotec Ltd's 2025-26 Annual Report details governance updates including a new independent director, AGM scheduled for September 29, 2026 via video conference, and electronic-only report distribution. The company maintains going concern status amid vaccine-related awards from UNICEF and PAHO, with provisions for impairments and bad debts totaling ₹674.99 million. It resolved an Apotex arbitration for $5 million while facing ongoing disputes with HV and Generium. Shareholding remains highly concentrated with promoters at 72.48%, and 99.76% of shares are dematerialized. No material changes or frauds were reported, though minor statutory filing delays occurred.

Panacea Biotec announced that shareholders without registered email addresses will receive a web link to access the Annual Report for FY2025-26 and the notice of the 42nd AGM scheduled for September 29, 2026 via video conferencing. The notice includes e-voting details and instructions to update contact details.